Brand-new skeleton 99MTC-FAPI diagnostic probe and use thereof in preparation of drug or reagent for diagnosing tumors
AssigneeNanjing Nuoyuan Medical Devices Co., Ltd
InventorsYueqing Gu, Yang Luo, Zihan Wu, Qiao Lin, Feng Wang, Pengjun Zhang, Zhihao Han
Life of this patent
Estimating the term…
Abstract
The present disclosure discloses a brand-new skeleton 99mTc-FAPI diagnostic probe and use thereof in the preparation of a drug or a reagent for diagnosing tumors, wherein the structural formula of a dimeric compound targeting FAP is shown by following formula. Compared with conventional FAP inhibitor radiopharmaceuticals, technetium-99m-labeled novel skeleton FAP inhibitor dimeric compound has a very high tumor uptake rate, high contrast between tumor and background and good in vivo biodistribution.
Claims5
A dimeric compound targeting FAP or a pharmaceutically acceptable salt thereof, wherein the dimeric compound targeting FAP has a structure as follows:
- wherein R1 is selected from cyano;
- R2 is selected from hydrogen, fluoro or chloro;
- R3 is selected from hydrogen or methyl;
- R4 is selected from hydrogen, methyl, ethyl, propyl, cyclopropyl or cyclobutyl;
- R5 and R6 are independently selected from hydrogen, methyl, fluoro or chloro;
- R7 and R8 are independently selected from hydrogen or methyl;
- L1 and L2 are independently selected from any one of:
- Y is selected from any one of:
- Q is a hydrogen atom or is used as a nuclide chelating group moiety, and is selected from any one of:
A dimeric compound targeting FAP and a pharmaceutically acceptable salt thereof, wherein the dimeric compound is selected from any one of:
Dependencies are inferred from the claim text.